FindTrial
Sign In

Life-2023-02 Esophagogastric Variceal Bleeding

Life-2023-02 Study on the Efficacy of Growth Inhibitors After Endoscopic Treatment of Acute Esophagogastric Variceal Bleeding

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06011980
Enrollment
33
Registered
2023-08-25
Start date
2023-08-31
Completion date
2026-08-10
Last updated
2023-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Esophageal Variceal Hemorrhage

Brief summary

Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Detailed description

Participants with acute esophagogastric variceal bleeding in 5 days and under stable status will be included in this study. All the patients will take CTP test to confirm the blood flow status of the portal vein before endoscopic treatment. After that they will be randomly divided into two groups: A. accept growth inhibitors after the endoscopic treatment for 5 days; B. no growth inhibitor will be applied after the treatment.

Interventions

DRUGGrowth Inhibitor

growth inhibitors for 250-500μg/h, ivgtt. for 5 days

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* acute esophagogastric bleeding with hepatic cirhosis; * stable status (no active bleeding)

Exclusion criteria

* endoscopic test limitation; * previous acute esophagogastric bleeding treatment history; * ICU; * pregnant; * Immunity disabled;

Design outcomes

Primary

MeasureTime frameDescription
rebleeding rate after the endoscopic treatment in Group A at 1 month1 month after the endoscopic treatmentrecord the rebleeding incidence in this group A; (Rate A1= the number of rebleeding participants/the number of all the participants)
rebleeding rate after the endoscopic treatment in Group A at 3 months3 months after the endoscopic treatmentrecord the rebleeding incidence in this group A; (Rate A2= the number of rebleeding participants/the number of all the participants)
rebleeding rate after the endoscopic treatment in Group A at 6 months6 months after the endoscopic treatmentrecord the rebleeding incidence in this group A; (Rate A3= the number of rebleeding participants/the number of all the participants)
rebleeding rate after the endoscopic treatment in Group B at 1 month1 month after the endoscopic treatmentrecord the rebleeding incidence in this group B; (Rate B1= the number of rebleeding participants/the number of all the participants)
rebleeding rate after the endoscopic treatment in Group B at 3 months3 months after the endoscopic treatmentrecord the rebleeding incidence in this group B; (Rate B2= the number of rebleeding participants/the number of all the participants)
rebleeding rate after the endoscopic treatment in Group B at 6 months6 months after the endoscopic treatmentrecord the rebleeding incidence in this group B; (Rate B3= the number of rebleeding participants/the number of all the participants)

Countries

China

Contacts

Primary ContactWEI WEI
wwze@zju.edu.cn15267175186

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026